# Shanghai Pharmaceuticals Holding Co., Ltd trials: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor, 14 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shanghai Pharmaceuticals Holding Co., Ltd: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-pharmaceuticals-holding-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 14
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 10, 2026 | NCT07754825 | A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Not yet recruiting | Acute Ischemic Stroke | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754825) |
| February 21, 2025 | NCT06839131 | A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects. | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 | Recruiting | Healthy Participants | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06839131) |
| July 5, 2024 | NCT06487455 | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 | Recruiting | Advanced Solid Tumor | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06487455) |
| July 3, 2024 | NCT06483373 | A Clinical Study of SPH7854 Granules in Healthy Subjects. | Shanghai Pharmaceuticals Holding Co., Ltd | Early phase 1 | Recruiting | Inflammatory Bowel Disease | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06483373) |
| May 30, 2024 | NCT06434597 | A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Recruiting | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06434597) |
| April 17, 2024 | NCT06372223 | A Food Effect Study of SPH5030 Tablets. | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 | Completed | Advanced Solid Tumor | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06372223) |
| February 20, 2024 | NCT06266923 | A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors. | Shanghai Pharmaceuticals Holding Co., Ltd | Early phase 1 | Completed | Advanced Solid Tumor | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06266923) |
| January 19, 2024 | NCT06214156 | A Clinical Study of T3011 in Subjects With Advanced Melanoma | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1/2 | Recruiting | Advanced Melanoma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06214156) |
| January 19, 2024 | NCT06214143 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1/2 | Recruiting | Advanced Solid Tumors | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06214143) |
| July 13, 2023 | NCT05944224 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1/2 | Recruiting | Advanced Solid Tumors | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05944224) |
| June 15, 2023 | NCT05905614 | Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1/2 | Completed | Advanced Solid Tumors | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905614) |
| May 24, 2023 | NCT05872347 | Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Recruiting | Breast Cancer Brain Metastases | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05872347) |
| May 16, 2023 | NCT05860465 | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2/3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05860465) |
| March 15, 2023 | NCT05770609 | A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Completed | Mild to Moderate Ulcerative Colitis | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05770609) |
| February 27, 2023 | NCT05744687 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2/3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 374 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05744687) |
| January 17, 2023 | NCT05686642 | Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Recruiting | Acute Ischemic Stroke | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05686642) |
| October 25, 2022 | NCT05593575 | Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Completed | Diabetic Kidney Disease | 305 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05593575) |
| October 25, 2022 | NCT05593562 | Study on Human Mass Balance of SPH3127 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1/2 | Completed | Primary Mild and Moderate Hypertension | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05593562) |
| May 3, 2022 | NCT05359068 | Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 3 | Completed | Essential Hypertension | 957 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05359068) |
| May 3, 2022 | NCT05359055 | Drug-drug Interaction Study of SPH3127 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1/2 | Completed | Drug Drug Interaction | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05359055) |
| February 17, 2022 | NCT05245058 | SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors | Shanghai Pharmaceuticals Holding Co., Ltd | Early phase 1 | Recruiting | HER2-positive Advanced Solid Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05245058) |
| December 6, 2021 | NCT05145361 | Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) | Shanghai Pharmaceuticals Holding Co., Ltd | Early phase 1 | Recruiting | NMO Spectrum Disorder | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05145361) |
| October 21, 2021 | NCT05088070 | Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 | Completed | Solid Tumor | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05088070) |
| September 16, 2021 | NCT05046314 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 2 | Completed | Sarcoma, Ewing | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05046314) |
| May 11, 2020 | NCT04382352 | B002 in Patients With HER2-positive Breast Cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 | Completed | Recurrent Breast Cancer, Metastatic Breast Cancer | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04382352) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 4 |
| Phase 1 | 11 |
| Phase 1/2 | 7 |
| Phase 2 | 10 |
| Phase 2/3 | 2 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Recruiting | 13 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 3 |
| Breast Neoplasms | 3 |
| Ischemic Stroke | 2 |
| Essential Hypertension | 2 |
| Spondylitis, Ankylosing | 1 |
| Arthritis, Rheumatoid | 1 |
| Diabetic Nephropathies | 1 |
| Sarcoma, Ewing | 1 |
| Recurrence | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Neuromyelitis Optica | 1 |
| Inflammatory Bowel Diseases | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Sawmills in the United States](https://specstream.ai/data/businesses/sawmills/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Indonesian restaurants in the United States](https://specstream.ai/data/businesses/indonesian-restaurants/united-states)
- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
- [Carpenters in the United States](https://specstream.ai/data/businesses/carpenters/united-states)
